Assess whether working capital should be a walk-away (4c6818)

SITUATION After add-backs that are just delayed opex, QoE add-backs the seller marked 'normalized' is the working evidence for IP diligence counsel's financial counterpart in a public acquirer facing HSR and sector regulators. Decide whether working capital should be a walk-away using only what QoE add-backs the seller marked 'normalized' actually supports.

DECISION IP diligence counsel's financial counterpart in a public acquirer facing HSR and sector regulators must choose Proceed / Reprice / Walk / Hold using QoE add-backs the seller marked 'normalized' after add-backs that are just delayed opex.

HYPOTHESES TO TEST 1. QoE add-backs the seller marked 'normalized' reads as Proceed once add-backs that are just delayed opex is lined up to the same M&A Due Diligence population. 2. QoE add-backs the seller marked 'normalized' is closer to Reprice after add-backs that are just delayed opex; Proceed would over-claim this Legal, IP, and Regulatory extract. 3. Walk is still live in QoE add-backs the seller marked 'normalized' for IP diligence counsel's financial counterpart in a public acquirer facing HSR and sector regulators. 4. QoE add-backs the seller marked 'normalized' is missing the fact IP diligence counsel's financial counterpart needs after add-backs that are just delayed opex; stop this M&A Due Diligence close.

ANALYSIS REQUIRED 1. Separate a one-off add-back from a recurring earnings issue in QoE add-backs the seller marked 'normalized'. 2. Map reps, earnout mechanics, and integration risk a public acquirer facing HSR and sector regulators would inherit. 3. Tie quality-of-earnings, working-capital, and contingent items in QoE add-backs the seller marked 'normalized' to working capital should be. 4. For this M&A Due Diligence Legal, IP, and Regulatory file, read QoE add-backs the seller marked 'normalized' against add-backs that are just delayed opex and write the one fact that would move working capital should be for IP diligence counsel's financial counterpart.

RECOMMENDATION Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Legal, IP, and Regulatory packet (QoE add-backs the seller marked 'normalized' after add-backs that are just delayed opex). If QoE add-backs the seller marked 'normalized' cannot force a M&A Due Diligence label under Legal, IP, and Regulatory, stop. If QoE add-backs the seller marked 'normalized' after add-backs that are just delayed opex cannot support Proceed versus Reprice on this M&A Due Diligence Legal, IP, and Regulatory close, IP diligence counsel's financial counterpart must do not proceed, reprice, or walk on a quality-of-earnings fact the packet does not carry.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on working capital should be, then the evidence in QoE add-backs the seller marked 'normalized', then the action for IP diligence counsel's financial counterpart - Hypothesis scorecard against QoE add-backs the seller marked 'normalized': supported / rejected / untestable - What changes working capital should be if add-backs that are just delayed opex is later withdrawn - Named option among Proceed, Reprice, Walk and the fact that kills the others